Thyroid Gland Disorder Treatment Market Overview
Thyroid Gland Disorder Treatment Market by Drug Type (Levothyroxine, Liothyronine, Propylthiouracil, Methimazole, Carbimazole, and Others), Disorder Type (Hypothyroidism and Hyperthyroidism), Route of Administration (Oral and Parenteral), Distribution Channel (Hospital and Retail Pharmacies and Online Pharmacies), and Geography (North America, Europe, Asia-Pacific, and Rest of the World) is expected to grow at a steady CAGR forecast till 2032 owing to the growing prevalence of thyroid disorders and increasing R&D activities and product launches by key players.
Explore the full Hypothyroidism treatment pipeline report and unlock strategic insights for informed decision-making today.
Thyroid Gland Disorder Treatment Market Valuation and Outlook
The thyroid gland disorder treatment market was valued at USD 2,303.63 million in 2024, growing at a CAGR of 3.26% during the forecast period from 2025 to 2032 to reach USD 2,967.06 million by 2032. The demand for Thyroid Gland Disorder Treatment is experiencing significant growth, driven by the rising prevalence of thyroid gland disorders such as hypothyroidism and hyperthyroidism. Increasing awareness about the importance of early and accurate diagnosis is further accelerating market growth. Moreover, a notable shift toward biologic therapies, which offer targeted and more effective treatment options, is transforming the therapeutic landscape. Combined with increasing investments and continuous innovation in the research and development of thyroid gland disorder therapies, this is fostering a highly favorable environment for market expansion. These factors collectively position the thyroid gland disorder treatment market for robust and sustained growth throughout the forecast period from 2025 to 2032.
Thyroid Gland Disorder Treatment Market Dynamics
The global burden of thyroid disorders continues to mount at an alarming rate. According to a recent study published in Endocrine Practice (2023), an estimated 200 million people worldwide were living with thyroid disease. Similarly, data from the British Thyroid Foundation (2023) indicated that approximately 1 in 20 people in the UK were affected by some form of thyroid disorder. In Australia, the prevalence is also significant – the Endocrine Society of Australia (2023) reported that hypothyroidism is the most common thyroid disorder, affecting 1 in 33 Australians, with a higher incidence among women and individuals over the age of 60. Additionally, the Australian Thyroid Foundation (2022) estimated that over 1 million Australians were living with an undiagnosed thyroid disorder.
The increasing prevalence of thyroid disorders across diverse regions is fueling the demand for effective treatment options, thereby accelerating the growth of the market. Understanding the Thyroid Gland Disorder Treatment Mechanism – particularly how hormone replacement and anti-thyroid agents restore physiological balance – remains central to the development of next-generation therapies.
In response, key market players are intensifying their focus on research and development to introduce innovative therapies. For instance, in May 2024, Xeris Biopharma announced positive topline Phase 2 clinical data for its investigational once-weekly subcutaneous levothyroxine (XP-8121), formulated using its proprietary XeriSol™ technology. This therapy aims to offer greater convenience and improved adherence in the treatment of hypothyroidism, reflecting the industry’s shift toward long-acting, patient-friendly treatment solutions.
However, the adverse effects of thyroid medications and stringent regulatory requirements for drug approval, among others, are some of the key constraints that may limit the growth of the thyroid gland disorder treatment market.
Thyroid Gland Disorder Treatment Market Segment Analysis
Thyroid Gland Disorder Treatment Market by Drug Type (Levothyroxine, Liothyronine, Propylthiouracil, Methimazole, Carbimazole, and Others), Disorder Type (Hypothyroidism and Hyperthyroidism), Route of Administration (Oral and Parenteral), Distribution Channel (Hospital and Retail Pharmacies and Online Pharmacies), and Geography (North America, Europe, Asia-Pacific, and Rest of the World)
In the drug type segment of the thyroid gland disorder treatment market, the levothyroxine category is estimated to account for the largest market share in 2024. This growth is primarily driven by the rising global prevalence of thyroid gland disorders and the critical role levothyroxine plays in their treatment.
Levothyroxine is the most widely prescribed hormone replacement therapy for managing thyroid disorders, particularly hypothyroidism. It functions by replacing the deficient thyroid hormone in patients whose bodies are unable to produce sufficient amounts naturally. By restoring normal thyroid hormone levels, levothyroxine helps normalize metabolic function and maintain overall physiological balance. This medication supports a range of essential biological processes, including metabolism regulation, energy production, body temperature control, and cardiovascular health. Consequently, it alleviates common symptoms associated with hypothyroidism, such as fatigue, weight gain, depression, and cognitive impairment.
Levothyroxine is not only the standard treatment for primary hypothyroidism but is also used in cases of secondary and tertiary hypothyroidism, underscoring its broad therapeutic relevance. The role of Thyroid Gland Disorder Treatment Medical Devices – including diagnostic tools such as thyroid function analyzers and ultrasound systems – further complements the pharmaceutical segment by enabling accurate monitoring and dose optimization.
In response to ongoing demand, key market players are actively investing in the development of new and improved formulations to enhance patient outcomes and reinforce their competitive positioning. For instance, in March 2023, Camber Pharmaceuticals expanded its product portfolio by launching Levothyroxine Sodium Tablets, USP, a critical therapy for the treatment of hypothyroidism and related thyroid disorders. Such developments reflect the industry’s commitment to advancing treatment options and improving patient adherence.
Given these factors, the levothyroxine segment is expected to generate significant revenue and serve as a major contributor to the overall growth of the thyroid gland disorder treatment market during the forecast period.
North America Expected to Dominate the Overall Thyroid Gland Disorder Treatment Market
North America is expected to hold the largest share of the global thyroid gland disorders treatment market in 2024, driven by a combination of key structural and strategic advantages. This dominance is mainly driven by the rising prevalence of thyroid disorders, such as hypothyroidism and hyperthyroidism, along with associated risk factors. Additionally, increased awareness initiatives, early diagnosis, and a strong focus on R&D activities and product launches by key market players are further strengthening North America’s leadership in this market.
According to the National Institutes of Health (2022), nearly 5 in 100 people aged 12 and older in the U.S. were living with hypothyroidism, though many cases present with mild or limited symptoms. The American Thyroid Association (2022) further reported that over 12% of the U.S. population will experience a thyroid disorder at some point in their lives, highlighting the growing need for accessible and effective treatment options.
Similarly, data from the Thyroid Foundation of Canada (2024) revealed that nearly 1 in 10 Canadians were affected by a thyroid-related condition. This rising prevalence across North America is a key driver of growth in the thyroid gland disorders treatment market. The increasing incidence of thyroid disorders is expected to elevate the demand for anti-thyroid drugs, which are essential in managing thyroid dysfunction. For example, in December 2022, Hikma Pharmaceuticals PLC launched Levothyroxine Sodium Injection in the U.S., available in ready-to-use 100 mcg/mL vials, offering a critical treatment option for patients requiring injectable therapy.
Collectively, the combination of increasing disease incidence and continuous product launches by major industry players is expected to drive robust growth in the North American thyroid gland disorders treatment market throughout the forecast period from 2025 to 2032.
Thyroid Gland Disorder Treatment Market Key Players
Some of the key Thyroid Gland Disorder Treatment Companies operating in the thyroid gland disorders treatment market include Pfizer Inc., AbbVie Inc., GSK plc, Merck & Co., Inc., Teva Pharmaceutical Industries Ltd., Eli Lilly and Company, Amneal Pharmaceuticals LLC, AstraZeneca, Amgen Inc., Hikma Pharmaceuticals PLC, Takeda Pharmaceutical Company Limited, Novartis AG, Exelixis, Inc., Sanofi, Viatris Inc., Provell Pharmaceuticals LLC, IBSA Pharma Inc., Tourmaline Bio, Inc., Azurity Pharmaceuticals, Inc., ADVANZ Pharma, and others.
Recent Developmental Activities in the Thyroid Gland Disorder Treatment Market
- In September 2024, Amgen announced that TEPEZZA® (teprotumumab, genetically recombined) received approval from Japan’s Ministry of Health, Labour and Welfare (MHLW) for the treatment of active thyroid eye disease (TED) with a high Clinical Activity Score (CAS).
- In June 2023, Xeris Biopharma Holdings, Inc. announced the initiation of a multi-center, open-label Phase 2 clinical trial for XP-8121, an investigational therapy for the treatment of adults with hypothyroidism. The company confirmed that the first participant has been dosed, marking a significant step forward in the development of this once-weekly subcutaneous levothyroxine formulation, designed to improve treatment adherence and patient outcomes in hypothyroidism management.
Download the comprehensive Hyperthyroidism market analysis report and discover growth opportunities shaping the future of thyroid care.
Conclusion
The global thyroid gland disorder treatment market is poised for sustained expansion through 2032, fueled by the growing prevalence of hypothyroidism and hyperthyroidism, rising awareness of early diagnosis, and continuous advancements in therapeutic development. Increasing investments in research and development, along with innovative product launches and biologic therapies, are reshaping the treatment landscape and improving patient outcomes. Levothyroxine continues to dominate the market due to its broad clinical application and effectiveness. Meanwhile, North America remains the leading regional market owing to strong healthcare infrastructure and high disease burden. Overall, ongoing innovation and expanding treatment accessibility are expected to drive consistent market growth globally.
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharmaceutical companies by providing comprehensive end-to-end solutions to improve their performance. It also offers healthcare consulting services that leverage market analysis to accelerate business growth and overcome challenges with practical approaches.
Media contact
Name: Abhishek kumar
E-mail:abhishek@delveinsight.com
